This is possibly because reperfusion is associated with a substantially more robust inflammatory response compared with ischemia alone,33 characterized by both increased myocardial IL‐6 mRNA transcription34 and plasma concentrations.35 The ASSAIL‐MI (Assessing the Effect of Anti‐IL‐6 Treatment in Myocardial Infarction) trial,36 which has enrolled patients with ST‐segment–elevation MI undergoing primary PCI, will help determine whether targeting IL‐6 in the context of early reperfusion is likely to be of therapeutic benefit. Here, IL6 is linked to myocardial infarction.